President Trump has demanded that 17 pharmaceutical companies reduce drug prices in the U.S., which are reportedly higher compared to other developed nations. A recent Executive Order aims to implement Most-Favoured-Nation (MFN) drug pricing for Americans, focusing on Medicaid and new drug launches.<\/p>\n
The administration asserts that lower international drug prices should benefit U.S. residents. Companies have been given until September 29, 2025, to adhere to these new pricing guidelines. Non-compliance will lead to the administration deploying measures to oppose what are described as exploitative pricing practices.<\/p>\n
Key demands include extending MFN pricing to Medicaid so that drugs reflect the lowest prices globally. Newly launched drugs should maintain MFN pricing across Medicare, Medicaid, and commercial payers. Excess profits from abroad must be redirected to benefit American patients and taxpayers. The U.S. government should acquire high-volume prescriptions at the same reduced prices available internationally.<\/p>\n
Pharmaceutical companies like Eli Lilly, Sanofi, Regeneron, Merck, Astrazeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol Myers, Abbvie, Novartis, Gilead Science, Boehringer Ingelheim, and EMD Serono received notices advising them of these requirements and impending deadlines.<\/p>\n
With this direct warning to 17 major drugmakers, we should expect a sharp increase in implied volatility across the pharmaceutical sector. This uncertainty creates a clear opportunity for derivative traders, particularly for names like Eli Lilly, Pfizer, and Merck. The short deadline of September 29, 2025, means market nervousness will likely build over the next eight weeks.<\/p>\n
Our immediate focus should be on protective put options for these specific stocks. This move serves as a hedge against potential price drops if the market believes these companies will be forced to lower U.S. revenue. We saw how the market reacted to the drug pricing negotiations under the Inflation Reduction Act in 2023 and 2024, which created significant headwinds for the sector.<\/p>\n
The threat is credible because U.S. drug prices are demonstrably higher than in other nations. A recent RAND Corporation study found that U.S. prices for brand-name drugs were, on average, 2.78 times higher than in comparable OECD countries. This statistic gives the administration a strong justification for its aggressive stance.<\/p>\n
Given that the U.S. market represents over 50% of global pharmaceutical profits for many of these companies, any forced price reduction is a direct threat to their bottom line. The demand to apply Most-Favored-Nation pricing to Medicaid would have an immediate and significant financial impact. Therefore, we should anticipate that the market will begin pricing in this risk well before the September deadline.<\/p>\n
Traders should look at option contracts that expire after the September 29 deadline to capture the full effect of the outcome. October and November 2025 expirations will be critical, as they will reflect either the relief of a resolution or the fallout from government enforcement action. We expect implied volatility to peak in the final weeks of September.<\/p>\n
This political pressure also impacts the broader sector, not just the 17 companies listed. We can use derivatives on ETFs like the Health Care Select Sector SPDR Fund (XLV) to play the wider trend. A bearish position on the sector index could be a sound strategy to mitigate risk from any single company’s specific response.<\/p>\n
Create your live VT Markets account<\/a>\u00a0and\u00a0start trading<\/a>\u00a0now. <\/b><\/p>\n","protected":false},"excerpt":{"rendered":" Trump orders 17 drugmakers to cut U.S. prices, enforcing global parity through Most-Favoured-Nation pricing policy.<\/p>\n","protected":false},"author":62,"featured_media":17025,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[59],"tags":[],"class_list":["post-27834","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-live-updates"],"acf":{"acf_article_selection_author":null},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/posts\/27834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/users\/62"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/comments?post=27834"}],"version-history":[{"count":0,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/posts\/27834\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/media\/17025"}],"wp:attachment":[{"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/media?parent=27834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/categories?post=27834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/tags?post=27834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}